期刊文献+

帕博昔布的合成 被引量:1

Synthesis of Palbociclib
原文传递
导出
摘要 尿嘧啶(2)经1,3-二溴-5,5-二甲基乙内酰脲(DBH)溴代得5-溴尿嘧啶(3),收率由文献的86%提高至95%;3经五氯化磷氯化得2,4-二氯-5-溴嘧啶(4),革除了剧毒且刺激性强的三氯氧磷,收率由文献的88%提高至99%;4与环戊胺发生取代反应得5-溴-2-氯-N-环戊基嘧啶-4-胺(5);以氯化钯代替文献的乙酸钯作催化剂,5与巴豆酸经Heck反应后,再经内酰胺化成环得2-氯-8-环戊基-5-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮(6),缩短了反应时间(由>36 h减少至6 h),收率也由80%提高至90%以上。6再经溴化、取代、Heck偶联、酸性水解以及脱保护反应制得帕博昔布(1),总收率52.1%(以2计)。 5-Bromouracil (3) was prepared via bromination of uracil (2) in the presence of 1,3-dibromo-5,5- dimethylhydantoin with a yield of 95 %. Then 2,4-dichloro-5-bromopyrimidine (4) was synthesized via chlorination of 3. In this step, phosphorus pentachloride was used instead of phosphoryl chloride so that the yield was increasd from 88 % to 99 % . 4 reacted with cyclopentylamine to give 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine (5). Then 5 was subjected to Heck reaction with crotonic acid followed by lactamization to afford 2-chloro-8-cyclopentyl-5- methylpyrido [2,3-d]pyrimidin-7 (8H)-one (6). In this step, palladium chloride was used instead of palladium acetate to shorten the reaction time from 〉36 h to 6 h and increase the yield from 80% to 〉90% . Palbociclib (1) was obtained after bromination of 6, substitution, Heck coupling reaction, acidic hydrolysis and deprotection with an overall yield of 52.1% (based on 2).
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第5期651-655,共5页 Chinese Journal of Pharmaceuticals
关键词 帕博昔布 周期蛋白依赖性激酶4/6抑制剂 乳腺癌 合成 palbociclib CDK4/6 inhibitor breast cancer synthesis
  • 相关文献

参考文献1

二级参考文献35

  • 1U.S. Food and Drug Administration. New molecular entityand new therapeutic biological product approvals for 2015[EB/OL]. [2016-01-01]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm.
  • 2Chekal BP, Ide ND. Solid forms of a selective CDK4/6inhibitor: WO, 2014128588A1 [P]. 2014-08-28.
  • 3Sakaguchi T,Tsuruoka A. Amorphous salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl) aminophenoxy] -7-methoxy-6-quinolinecarboxamide and process for producing the same:WO, 2006137474A1 [P]. 2006-12-28.
  • 4Acemoglu M, Bajwa JS, Karpinski P,et al. Saltsof AT-hydroxy-3- [4 - [ [ [2- (2-methyl-lff-indol-3-yl) ethyl] amino] methyl] phenyl] -2^-2-propenamide: WO,2007146715A1 [P]. 2007-12-21.
  • 5Gao WQ,Jiang JQ, Wan YQ, et al. Compounds andcompositions as Hedgehog pathway modulators: WO,2007131201A2 [P]. 2007-11-15.
  • 6Bajwa JS, De La Cruz M, Dodd SK, et al. Salts of N- [6-(ci5-2,6-dimethylmorpholin-4-yl) pyridin-3-yl] -2-methyl-4 - (trifluoromethoxy) [1,1 -biphenyl] -3-carboxamide: WO,2010033481A1 [P]. 2010-03-25.
  • 7Yano S, Kazuno H, Sato T, et al. Synthesis and evaluation of6-methylene-bridged uracilderivatives. Part 2: Optimizationof inhibitors of human thymidine phosphorylase and theirselectivity with uridine phosphorylase [J]. Bioorg MedChem, 2004,12 (13): 3443—3450.
  • 8Cuevas C, Perez M, Martin MJ, et al. Synthesis ofecteinascidin ET-743 and phthalascidin Pt-650 fromcyanosafracin B [J]. Org Lett, 2000,2(16): 2545—2548.
  • 9Naganathan S, Guz N, Pfeiffer M. Novel process formaking compounds for use in the treatment of cancer: WO,2014059422A1 [P]. 2014-04-17.
  • 10Finlay MRV, Anderton M, Ashton S, et al. Discovery of apotent and selective EGFR inhibitor (AZD9291) of bothsensitizing and T790M resistance mutations that sparesthe wild type form of the receptor [J]. J Med Chem, 2014,57(20): 8249—8267.

共引文献10

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部